A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium

Blood. 2018 Mar 8;131(10):1145-1148. doi: 10.1182/blood-2017-09-803809. Epub 2018 Jan 16.

Weili Sun^{1

2

3}, Timothy Triche Jr^{3

4

5}, Jemily Malvar^{2

3}, Paul Gaynon^{2

3}, Richard Sposto^{2

3

6}, Xiaojing Yang⁷, Henrique Bittencourt⁸, Andrew E Place^{9

10}, Yoav Messinger¹¹, Chris Fraser¹², Luciano Dalla-Pozza¹³, Bodour Salhia^{3

4}, Peter Jones^{2

5}, Alan S Wayne^{2

3}, Lia Gore^{14

15}, Todd M Cooper¹⁶, Gangning Liang³

¹ Department of Pediatrics, City of Hope National Medical Center, Duarte, CA.
² Children's Center for Cancer and Blood Diseases, Children Hospital Los Angeles, Los Angeles, CA.
³ USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.
⁴ Translational Genomics Research Institute, Phoenix, AZ.
⁵ Van Andel Research Institute, Grand Rapids, MI.
⁶ Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
⁷ Zymo Research Corporation, Irvine, CA.
⁸ Sainte-Justine University Hospital Center, Montreal, QC, Canada.
⁹ Dana-Farber Cancer Institute, Boston, MA.
¹⁰ Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA.
¹¹ Children's Hospital & Clinics of Minnesota, Minneapolis, MN.
¹² Lady Cilento Children's Hospital, Brisbane, QLD, Australia.
¹³ The Children's Hospital at Westmead, Westmead, NSW, Australia.
¹⁴ Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO.
¹⁵ Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO; and.
¹⁶ Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, WA.

No abstract available

Publication types